<DOC>
	<DOCNO>NCT01270867</DOCNO>
	<brief_summary>To determine Trevo Retriever good good Merci Retriever restore blood flow brain patient experience acute ischemic stroke large vessel .</brief_summary>
	<brief_title>Randomized Trial Evaluating Performance Trevo Retriever Versus Merci Retriever Acute Ischemic Stroke</brief_title>
	<detailed_description>The TREVO 2 protocol design assess safety effectiveness Trevo Retriever device determine substantially equivalent predicate Merci Retriever . The trial utilized Primary Effectiveness Endpoint revascularization composite Primary Safety Endpoint include procedure-related serious adverse event occur within 24 hour procedure . Subjects present enrol center large ischemic stroke screen eligibility study . If subject meet eligibility criterion , Informed Consent obtain prior commence angiogram . If inclusion/exclusion criterion confirm , include angiographic criterion , subject randomized.The Primary Effectiveness Endpoint successful revascularization target occlusion , use TICI score . Success determine central Core Lab.The Primary Safety Endpoint composite endpoint , describe protocol `` Incidence procedure-related serious adverse event ( PRSAEs ) 24 hour post procedure ( -6/+12 hour ) define : vascular perforation intramural arterial dissection , symptomatic ICH , embolization previously uninvolved territory , access site complication require surgical repair blood transfusion , intra-procedural mortality , device failure ( vivo breakage ) , complication judge Clinical Events Committee ( CEC ) related procedure . ''</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Key Patient present clinical sign symptom consistent diagnosis Acute Ischemic Stroke , : Patient fail IV tPA therapy Or Patient contraindicate IV tPA administration NIHSS 8 &lt; NIHSS &lt; 29 Anticipated life expectancy least 6 month No significant prestroke disability ( mRS &lt; 1 ) Written inform consent participate give patient legal representative Angiographic confirmation persistent large vessel occlusion internal carotid , middle cerebral ( M1 and/or M2 segment ) , basilar and/or vertebral artery Treatable within 8 hour symptom onset , define first pas make assign study device Key Abnormal blood pressure and/or blood coagulation lab value Pregnancy Patient participate another investigational drug device study More 1/3 MCA equivalent nonMCA territory Baseline evidence significant mass effect midline shift , hemorrhage , intracranial tumor Bilateral stroke</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Ischemia</keyword>
	<keyword>Stroke</keyword>
	<keyword>Ischemic Stroke</keyword>
	<keyword>Mechanical Thrombectomy</keyword>
	<keyword>Brain</keyword>
	<keyword>Brain clot</keyword>
	<keyword>Cerebrovascular disease</keyword>
	<keyword>Recanalization</keyword>
	<keyword>Revascularization</keyword>
</DOC>